NYSE:BHVN - New York Stock Exchange, Inc. - VGG1110E1079 - Common Stock - Currency: USD
22.85
+0.4 (+1.78%)
The current stock price of BHVN is 22.85 USD. In the past month the price increased by 11.19%. In the past year, price decreased by -43.84%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.18B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 256 full-time employees. The company went IPO on 2022-09-23. The company is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
BIOHAVEN LTD
215 Church Street
New Haven CONNECTICUT 06510 US
CEO: Vlad Coric
Employees: 239
Company Website: https://www.biohaven.com/
Investor Relations: https://ir.biohaven.com/
Phone: 12034040410
The current stock price of BHVN is 22.85 USD. The price increased by 1.78% in the last trading session.
The exchange symbol of BIOHAVEN LTD is BHVN and it is listed on the New York Stock Exchange, Inc. exchange.
BHVN stock is listed on the New York Stock Exchange, Inc. exchange.
22 analysts have analysed BHVN and the average price target is 61.67 USD. This implies a price increase of 169.89% is expected in the next year compared to the current price of 22.85. Check the BIOHAVEN LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOHAVEN LTD (BHVN) has a market capitalization of 2.33B USD. This makes BHVN a Mid Cap stock.
BIOHAVEN LTD (BHVN) currently has 239 employees.
BIOHAVEN LTD (BHVN) has a support level at 21.21 and a resistance level at 23.4. Check the full technical report for a detailed analysis of BHVN support and resistance levels.
The Revenue of BIOHAVEN LTD (BHVN) is expected to grow by 237.87% in the next year. Check the estimates tab for more information on the BHVN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BHVN does not pay a dividend.
BIOHAVEN LTD (BHVN) will report earnings on 2025-05-09, before the market open.
BIOHAVEN LTD (BHVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.39).
The outstanding short interest for BIOHAVEN LTD (BHVN) is 8.85% of its float. Check the ownership tab for more information on the BHVN short interest.
ChartMill assigns a technical rating of 1 / 10 to BHVN. When comparing the yearly performance of all stocks, BHVN is a bad performer in the overall market: 90.9% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to BHVN. While BHVN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months BHVN reported a non-GAAP Earnings per Share(EPS) of -9.39. The EPS decreased by -65.9% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -137.61% | ||
ROE | -199.89% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 87% to BHVN. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 25.79% and a revenue growth 237.87% for BHVN